RxDoctor Payments Data

Sunket Ahkee, MD

Infectious Disease · Boynton Beach, FLNPI 1023111580

Payments from drug & device makers

$7,811in general payments, 2019–2025

Across 329 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Merck$891
  • Gilead$834
  • Johnson & Johnson$726
  • Cipla USA Inc.$720
  • Insmed, Inc.$622
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$7,71699%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,811 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$655,803
Medicare patients
988
Services billed
507,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine378$1,084,824
BiktarvyBictegrav/Emtricit/Tenofov Ala195$789,204
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf113$541,047
JulucaDolutegravir/Rilpivirine55$213,093
CabenuvaCabotegravir/Rilpivirine24$140,025
DescovyEmtricitabine/Tenofov Alafenam45$97,605
TivicayDolutegravir Sodium37$85,867
Daptomycin105$66,657
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$62,266
PrezcobixDarunavir/Cobicistat15$60,835
OdefseyEmtricitab/Rilpiviri/Tenof Ala16$57,818
IsentressRaltegravir Potassium18$34,196
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$28,832
Meropenem55$16,562
ErtapenemErtapenem Sodium23$15,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Cabenuva, Tivicay$1,799$1,523,809494 claims
GileadBiktarvy, Descovy, Genvoya$834$949,075254 claims
Janssen Products, LPSymtuza$395$541,047113 claims
Johnson & JohnsonPrezcobix$726$60,83515 claims
MerckIsentress$891$34,19618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →